Placebo News and Research

RSS

Women with heart problems at higher cancer risk after Omega-3 and vitamin B supplementation

However, women with a previous history of cardiovascular pathologies seem to have a higher cancer risk after five years of supplementation. The research is published in detail in the Archives of Internal Medicine.

18 Feb 2012

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

17 Feb 2012

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

RUMC conducts early phase trial of MSDC-0160 for dementia

Researchers at Rush University Medical Center are conducting an early phase clinical trial of a novel drug therapy for patients with dementia due to Alzheimer's disease. The drug is a new compound called MSDC-0160, which is an insulin sensitizer that modulates mitochondrial metabolism.

16 Feb 2012

UCSD opens lidocaine and amiodarone clinical trial to prevent SCA

Sudden Cardiac Arrest (SCA) is the leading cause of death in the United States. This form of heart attack kills 325,000 people every year, representing one death every two minutes. Almost all SCA victims die before they even reach a hospital. To identify a drug that paramedics can use in the field, UC San Diego Health System has opened a clinical trial to evaluate two medications to help restore the heart beat.

15 Feb 2012

Amoxicillin not effective for patients with acute rhinosinusitis

Treatment with the antibiotic amoxicillin for patients with acute uncomplicated rhinosinusitis (inflammation of the nasal cavity and sinuses) did not result in a significant difference in symptoms compared to patients who received placebo, according to a study in the February 15 issue of JAMA. Antibiotics are commonly used to treat this condition even though there is limited evidence supporting their effectiveness.

15 Feb 2012

Paricalcitol does not improve clinical outcomes for patients with CKD

Patients with chronic kidney disease who received the vitamin D compound paricalcitol for up to 48 weeks did not show improvement on measures of cardiac structure, function, or left ventricular mass, compared to patients who received placebo, according to a study in the February 15 issue of JAMA.

15 Feb 2012

Tetrahydrobiopterin plays a key role in arterial health of women

Researchers studying why arteries stiffen in postmenopausal women have found a specific chemical cofactor that dramatically improves vascular function.

15 Feb 2012

Antibiotic prescriptions do not reduce sinus symptoms

Antibiotics that doctors typically prescribe for sinus infections do not reduce symptoms any better than an inactive placebo, according to investigators at Washington University School of Medicine in St. Louis.

15 Feb 2012

FDA accepts Gilead's Truvada sNDA and grants Priority Review

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.

14 Feb 2012

Trevena commences TRV130 Phase I clinical trial for severe post-operative pain

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today the initiation of a Phase I clinical trial of TRV130, a novel candidate designed for the intravenous treatment of moderate-to-severe post-operative pain.

13 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

Santarus initiates enrollment in UCERIS Phase IIIb study for ulcerative colitis

Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.

13 Feb 2012

Pioglitazone can prevent long term effects of maternal obesity on offspring

In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in Dallas, Texas, researchers will report findings that show that short therapy with the anti-diabetic medication Pioglitazone can prevent the long term effects of maternal obesity on offspring.

13 Feb 2012

Tai chi could benefit Parkinson’s disease patients

A new study found that a six-month program of Tai Chi exercises helped people with various stages of Parkinson's disease improve stability, their ability to walk and reduced the frequency of falls.

12 Feb 2012

PAP improves attention, anxiety and QOL in children with OSAS

Children and adolescents with obstructive sleep apnea had substantial improvements in attention, anxiety and quality of life after treatment with positive airway pressure (PAP)—a nighttime therapy in which a machine delivers a stream of air through a mask into the nose.

10 Feb 2012

FDA panel votes against Amgen’s Xgeva in prostate cancer

An FDA panel of oncologists has voted against a new use for Amgen's Xgeva in prostate cancer on Wednesday, saying the drug's ability to slow the spread of the disease did not translate into meaningful benefits for patients. Xgeva is already approved to prevent fractures in cancerous bones, and for osteoporosis, in a different formulation called Prolia.

9 Feb 2012

Researchers examine effectiveness of Omega 3 in treating psychiatric symptoms

Researchers at Zucker Hillside Hospital's Recognition and Prevention (RAP) Program who have worked with teenagers at risk for serious mental illness for the past decade are now studying the effectiveness of Omega 3 fatty acids (fish oil) for treating psychiatric symptoms.

9 Feb 2012

Genzyme announces four-year data from eliglustat tartrate phase 2 trial on Gaucher disease type 1

Genzyme, a Sanofi company, announced today four-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate.

8 Feb 2012

Exemestane has negative effect on postmenopausal women's bone health

Exemestane, a drug used in the prevention of breast cancer in postmenopausal women, has a negative effect on bone density and structure in these women, despite calcium and vitamin D supplements.

8 Feb 2012